N/A N=60 Use of Pedometers to Measure and Increase Walking Among Patients With ESRD
End-stage Renal Disease
Primary: Physical Activity — 1474; 180 steps/day — p=<0.01
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=40 Social Media Intervention for Postpartum Depression
Postpartum Depression · Parenting
Primary: Attendance — 83.3; 3.3 percentage of participants
N/A N=63 HIV Adherence Bottle Intervention Trial
HIV-1-infection · Adherence, Medication
Primary: Change in Tenofovir Diphosphate (TFV-DP) Drug Levels — 1230; 1108; 1887; 1084 fmol/punch — p=0.070
N/A N=122 AutoSet for Her Quality of Life Clinical Trial
Obstructive Sleep Apnea
Primary: Assessment of Quality of Life Using the Functional Outcomes of Sleep Questionnaire (FOSQ) — 1.9 score on a scale
Phase 2 N=12 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
Gastroenteropancreatic Neuroendocrine Tumors
Primary: Number of Participants Reported With Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Drug Reactions (ADRs) — 6; 0; 5 Participants
Phase 2 N=30 Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer
Breast Cancer Metastatic
Primary: Progression-free Survival (PFS) — 5 months
Phase 2 N=415 ARJ C13 Urea Breath Test System
H. Pylori Infection
Primary: Overall Percent Agreement — 98.40; 99.20 percentage of pos. agreement
N/A N=2,462 A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.
Diphtheria
Primary: Number of Subjects Reporting Gestational Diabetes — 10; 22 Participants — p=0.1147
N/A N=287 Improving Goals of Care Discussion in Advanced Cancer Patients
Primary Stage IV Hepatobiliary · Esophageal · Colorectal Cancer
Primary: Number of Participants Who Perceived Increased Goals of Care Discussions — 43; 34 Participants
N/A N=320 Colon Capsule Endoscopy (CCE) Versus Computed Tomographic Colonography (CTC) in the Identification of Colonic Polyps in a Screening Population.
Colorectal Cancer Screening
Primary: Number of Participants With an Actionable Lesion on CCE vs. CTC Confirmed by Optical Colonoscopy — 34; 11 Participants
N/A N=40 Safety and Efficacy of Cryoablation for Metastatic Lung Tumors
Metastatic Lung Cancer
Primary: Local Tumor Control for Each Index Tumor as Measured by Imaging at Month 60 — 80.0; 45.0; 15.0; 20.0 percentage of tumors
Phase 4 N=19 Hypoxic Pulmonary Vasoconstriction Pilot Study
Emphysema
Primary: Perfused Blood Volume Assessed for a Change in Lung Inflammation Pre and Post Dose Sildenafil Administration — 0.37; 0.42 coefficient of variation — p=<0.05
Phase 2 N=28 TAS-102 in Treating Advanced Biliary Tract Cancers
Cholangiocarcinoma · Stage III Gallbladder Cancer AJCC v7 · Stage IIIA Gallbladder Cancer AJCC v7
Primary: 16-Week Progression-free Survival (PFS) Rate — 32.0 percentage of patients
N/A N=562 Screening for Hesitancy to Optimize Talk
Preventive Health Services
Primary: Child's Mean Percent Days Under-immunized — 19.1; 25.2 percentage of days under-immunized — p=.29
Phase 2 N=180 Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732461 in Healthy HIV Seronegative Volunteers
AIDS · HIV Infections
Primary: Number of Subjects With Any and Grade 3 Solicited Local Symptoms — 2; 0; 2; 49 Participants